MedCity News January 3, 2024
Medical device startup CardioMech raised $13 million to advance the development and validation of its flagship device, which is designed to treat degenerative mitral valve regurgitation. The catheter-based device seeks to offer an uncomplicated, direct procedure for patients eligible for open-heart surgery as well as those considered eligible for the surgery.
Medical device startup CardioMech announced this week that it has raised $13 million in new capital, bringing its total funding to $42 million. With the fresh funds, the company hopes to advance the development and validation of its flagship device, which is designed to treat mitral valve disease.
Founded in 2015, CardioMech is based in Norway and has a fully owned subsidiary in Minnesota. All of the company’s research...
Today's Sponsors
Today's Sponsor